glp-1 news september 30 2025 Shortage = Over Lilly hikes revenue forecasts on

Yes - both compounds are dosed once weekly and the schedules line up well

While GLP-1 drugs deliver fast, visible metabolic outcomes, they leave the underlying fiber gap unresolved

The Chronic Pain or Injury Patient Patients managing chronic pain or recovering from injury may benefit from peptide therapies such as BPC-157, TB-500 (Thymosin Beta-4) and AOD-9604, which are commonly used to support tissue repair, regulate inflammation and promote recovery

It is uncertain if this early worsening can also occur for nAMD, and this would be of interest to investigate in a large prospective study in patients with diabetes